US · Basic Materials · Specialty Chemicals
EPS came in at 1.74 against a street estimate of 1.31 — a beat of 32.8%.
Analysts rate Ingevity Corp a buy (3 buy, 1 hold, 0 sell out of 4) with an average price target of $89.00.
| Fund | Stake |
|---|---|
| BlackRock Inc | 15.41% |
| Vanguard Portfolio Management, LLC | 6.33% |
| Vanguard Capital Management, LLC | 4.60% |
| Wellington Management Company LLP | 4.35% |
| State Street Corp | 4.24% |
| American Century Companies Inc | 4.17% |
| Millennium Management LLC | 3.36% |
| Segall Bryant & Hamill | 3.23% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 | 2026-07-30 |
| Results announced · Q3 2026 | 2026-07-29 |
| Board / officer change · Q2 2026 | 2026-06-24 |
| Quarterly report · Q1 2026 | 2026-05-07 |
| Results announced · Q2 2026 | 2026-05-06 |
| Board / officer change · Q2 2026 | 2026-05-04 |
| Proxy statement · Q2 2026 | 2026-03-17 |
| Annual report FY2025 | 2026-02-26 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Ingevity Corp — free to start.
Google PlayApp StoreData updated 2026-08-05.